Compare EOG Resources Inc (EOG) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Neurocrine Biosciences Inc — how do they compare? EOG Resources Inc trades at $148.57 (market cap $75.64B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: EOG Resources Inc is far larger — about 5.2× Neurocrine Biosciences Inc's market cap, and EOG Resources Inc pays a 2.83% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and Neurocrine Biosciences Inc for 23 Days on average.
| EOG | NBIX | |
|---|---|---|
Market Cap | $75.64B | $14.60B |
Volume | 2,041,336 | 1,075,694 |
Sector | Energy | Health |
52-Week High | $153.74 | $185.50 |
52-Week Low | $101.78 | $123.10 |
Typical Hold Time | 59 Days | 23 Days |
Enterprise Value | $78.99B | $14.61B |
Dividend Yield | 2.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $148.51, up 2.93% today, with a bullish technical signal from moving averages and strong fundamental metrics including a P/E of 11.22 and net income margin of 25.81%. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $5.07 exceeding expectations. Recent news highlights robust operational execution and disciplined capital allocation, with a CFO transition announced in September 2026.
Outlook remains positive with a consensus price target of $164.77, offering ~11% upside. Key opportunities include 5% oil volume growth guidance and strong free cash flow generation. Risks involve oil price volatility, as seen in recent price retreats, and execution of leadership transition. The stock presents a compelling value with no sell ratings among 66 analysts.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
